CRY CryoLife Inc

ATLANTA, Sept. 4 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE:CRY), a biomaterials, medical device and tissue processing company, announced today that Philip A. Theodore has been named vice president, general counsel, effective September 4, 2007. Mr. Theodore will report directly to Steven G. Anderson, chairman, president and chief executive officer of the Company. As general counsel, Mr. Theodore will be responsible for all corporate legal and governance activities, and will be involved in the execution of the Company's strategic growth plan, including acquisitions and other external transactions. "We are delighted that Phil has joined our corporate leadership team at Cryolife," said Steve Anderson. "His extensive experience in the life sciences industry, and in mergers, acquisitions and other transactions, will be key as the Company continues to grow its business and leverage its strengths in its core marketplaces." Mr. Theodore gained his life sciences expertise while serving as vice president, general counsel and corporate secretary of Serologicals Corporation, a global provider of biological products, enabling technologies and services, from January 2004 through July 2006, when Serologicals was acquired by a competitor. Most recently, Mr. Theodore was senior vice president and general counsel of John H. Harland Company, a New York Stock Exchange traded company that was acquired by a competitor on May 1, 2007. Mr. Theodore practiced law in the Atlanta office of King & Spalding, LLP for 22 years, representing both buyers and sellers in mergers, acquisitions and other transactions, including various financing transactions. He joined King & Spalding LLP in 1981, becoming partner in 1986. About CryoLife, Inc. Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community. For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com/ CryoLife Media Contacts: D. Ashley Lee Executive Vice President, Chief Operating Officer and Chief Financial Officer CryoLife, Inc. Phone: 770-419-3355 Katie Brazel Fleishman-Hillard Phone: 404-739-0150 DATASOURCE: CryoLife, Inc. CONTACT: D. Ashley Lee, Executive Vice President, Chief Operating Officer and Chief Financial Officer, CryoLife, Inc., +1-770-419-3355; or Katie Brazel of Fleishman-Hillard, +1-404-739-0150, for CryoLife, Inc. Web site: http://www.cryolife.com/

Copyright